tipifarnib has been researched along with Lymphoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allmer, C; Ansell, SM; Colgan, JP; Ding, H; Gupta, M; Habermann, TM; Hohl, R; Inwards, DJ; Johnston, PB; Kaufmann, SH; Kurtin, PJ; Link, BK; Loegering, D; Markovic, SN; Maurer, MJ; Micallef, IN; Nowakowski, GS; Peterson, K; Porrata, LF; Schneider, P; Tang, H; Thompson, CA; Weiner, G; Witzig, TE | 1 |
1 trial(s) available for tipifarnib and Lymphoma
Article | Year |
---|---|
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult | 2011 |